New horizons in LUTS

**Poster Session 22**

**Location:** Room Madrid (Hall B2, level 0)

**Chairs:**
- F. Cruz, Porto (PT)
- M.J. Drake, Bristol (GB)
- A. Ruffion, Pierre-Bénite (FR)

**Aims and objectives of this presentation**
Recent advances in the area of bladder pathophysiology, pharmacology and stem cell therapy will be presented and discussed.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

**271**

**Sphingosine-1-phosphate, a new biomarker of detrusor overactivity in patients with multiple sclerosis**

**By:** Sanson S.¹, Roumi guié M.¹, Ballouhey Q.², Castel-Lacanal E.³, Jaafar A.⁴, Tack Y.⁴, Game X.¹

**Institutes:** CHU Rangueil, Dept. of Urology, Toulouse, France, ¹CHU, Dept. of Pediatric Surgery, Limoges, France, ²CHU Rangueil, Dept. of Physical Medicine and Rehabilitation, Toulouse, France, ³CHU Rangueil, Dept. of Physiological Functional Exploration, Toulouse, France

**272**

**Differences in organisation and phenotypes of interstitial cells in bladder lamina propria between human and laboratory animals**

**By:** Gevaert T.¹, Steiner C.², Vanstreels E.³, Pintelon I.⁴, Timmermans J-P.⁴, Neuhaus J.², De Ridder D.¹

**Institutes:** ¹UZ Leuven, Dept. of Urology, Leuven, Belgium, ²University of Leipzig, Dept. of Urology, Leipzig, Germany, ³KU Leuven, Dept. of Laboratory of Virology and Chemotherapy (Rega Institute), Leuven, Belgium, ⁴University of Antwerp, Dept. of Veterinary Sciences, Antwerp, Belgium

**273**

**Altered muscarinic signalling in the urinary bladder of mouse models of Alzheimer’s disease**

**By:** Hohnen R.¹, Zare A.¹, Stevens J.¹, Losen M.¹, Meriaux C.¹, Rahnama'i M.S.², Van Koeveringe G.²

**Institutes:** ¹Maastricht University, Dept. of Neuroscience, Maastricht, The Netherlands, ²Maastricht University Medical Centre, Dept. of Urology, Maastricht, The Netherlands

**274**

**Measurement of endocannabinoids levels during treatment of bladder hyperactivity induced by cystitis with FAAH inhibitors and evaluation of the cannabinoid receptor and TRPV1 roles**

**By:** Charrua A.¹, Matos R.¹, Marczylo T.², Nagy I.³, Cruz F.¹

**Institutes:** ¹Faculty of Medicine of University of Porto, Dept. of Experimental Biology, Porto, Portugal, ²Public Health England, Chilton, United Kingdom, ³Faculty of Medicine, Imperial College of London, Dept. of Surgery & Cancer, London, United Kingdom

**275**

**Up-regulation of prostatic cannabinoid receptor type 2 following capsaicin-induced prostatitis in castrated and non-castrated rats**

**By:** Lin T.L.

**Institutes:** National Yang-Ming University Taipei Veterans Gen Hospital, Dept. of Urology, Taipei, Taiwan

**276**

**Does TRP channel play a role of extracellular calcium sensing in urethral smooth muscle?**

**By:** Kajio ka S., Hayashi M., Maki T., Takahashi R., Etoh M.

**Institutes:** Kyushu University, Dept. of Urology, Fukuoka, Japan
Mouse model with ketamine-induced voiding dysfunction demonstrates intact urothelial barrier function  
By: Rajandram R.\textsuperscript{1}, Ong T.A.\textsuperscript{1}, Razack A.\textsuperscript{1}, Maciver I.B.\textsuperscript{2}, Zeidel M.\textsuperscript{2}, Yu W.\textsuperscript{2}  
Institutes: \textsuperscript{1}University of Malaya, Dept. of Surgery, Kuala Lumpur, Malaysia, \textsuperscript{2}Beth Israel Deaconess Medical Center and Harvard Medical School, Dept. of Medicine, Boston, United States of America

Safety and effectiveness of mirabegron in patients with overactive bladder (OAB): Results of two Japanese post-marketing surveys  
By: Kato D.\textsuperscript{1}, Katoh T.\textsuperscript{2}, Kuwamoto K.\textsuperscript{1}, Nozawa Y.\textsuperscript{1}, Tabuchi H.\textsuperscript{1}, Kuroishi K.\textsuperscript{1}  
Institutes: \textsuperscript{1}Astellas Pharma Inc, Medical Affairs, Tokyo, Japan, \textsuperscript{2}International University of Health and Welfare, Mita Hospital, Cardiovascular Centre, Tokyo, Japan

Bladder acellular matrix grafts seeded with adipose-derived stem cells and incubated intraperitoneally promote the regeneration of bladder smooth muscle in a rat model of bladder augmentation  
By: Zhou Z.\textsuperscript{2}, Da J.\textsuperscript{2}, Zhao Y.\textsuperscript{2}, Zhang M.\textsuperscript{2}, Xiao D.\textsuperscript{2}, Wang Q.\textsuperscript{2}, Wang Z.\textsuperscript{2}, Lu M.\textsuperscript{1}  
Institutes: \textsuperscript{1}Shanghai 9th People’s Hospital, Shanghai, China, \textsuperscript{2}Shanghai 9th People’s Hospital, Dept. of Urology, Shanghai, China

Advanced properties of urine derived stem cells compared to adipose tissue derived stem cells in terms of cell proliferation, immune modulation and multi differentiation  
By: Choi S.H.\textsuperscript{1}, Chung J.-W.\textsuperscript{1}, Lee J.N.\textsuperscript{1}, Ha Y.-S.\textsuperscript{1}, Kim B.S.\textsuperscript{1}, Kim H.T.\textsuperscript{1}, Kim T.-H.\textsuperscript{1}, Yoo E.S.\textsuperscript{1}, Kwon T.G.\textsuperscript{1}, Chung S.K.\textsuperscript{1}, Kim B.W.\textsuperscript{1}, Cho D.-H.\textsuperscript{2}, Kim J.S.\textsuperscript{3}  
Institutes: \textsuperscript{1}Kyungpook University Hospital, Dept. of Urology, Daegu, South Korea, \textsuperscript{2}CHA Gumi Medical Center, Dept. of Urology, Gumi-Si, South Korea, \textsuperscript{3}Daegu Fatima Hospital, Dept. of Urology, Daegu, South Korea

Functional smooth muscle cells differentiated from adipose derived stem cells: The importance of autophagy  
By: Salemi S., Mortezavi A., Sulser T., Eberli D.  
Institutes: University Hospital Zürich, Dept. of Urology, Zurich, Switzerland

Summary and context  
F. Cruz, Porto (PT)